MedTrace Logo

Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children

NCT00163618 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2015-05-21

No results posted yet for this study

Summary

The objective of this study is to assess the TBE antibody persistence approximately three years after administration of a TBE booster vaccination with FSME-IMMUN 0.25 ml Junior in children who received either 0.25 mL or 0.5 mL TicoVac for their primary vaccination series in Study 146A.

Conditions

  • Encephalitis, Tick-borne

Interventions

BIOLOGICAL

Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl

Sponsors & Collaborators

Principal Investigators

  • Baxter BioScience Investigator · Baxter Healthcare Corporation

Eligibility

Min Age
7 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-06-30
Completion
2006-07-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00163618 on ClinicalTrials.gov